文献速递消化系统肿瘤

Ⅰ至Ⅲ期结直肠癌患者血浆游离DNA超深度测序分析

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
PubMed 文献 · JAMA Oncol · 2019-01-01

这项前瞻性多中心队列研究纳入130例Ⅰ至Ⅲ期结直肠癌患者,采用个体化多重PCR二代测序超深度检测血浆游离DNA中的循环肿瘤DNA(ctDNA)。术后第30天ctDNA阳性者复发风险显著高于阴性者(HR 7.2),辅助化疗后ctDNA阳性者复发风险更高(HR 17.5),监测期间ctDNA阳性者复发风险超过40倍(HR 43.5),且ctDNA可较标准影像学提前最多16.5个月发现复发。

要点

  • 术前ctDNA在108/122例(88.5%)可检出,纵向ctDNA分析识别了14/16例(87.5%)复发。
  • 术后第30天ctDNA阳性者复发风险为阴性者的7.2倍(HR 7.2,95%CI 2.7-19.0,P<.001)。
  • 辅助化疗后ctDNA阳性者全部7例复发,监测期ctDNA阳性者复发风险为阴性者43.5倍。

核心结论

  • ctDNA分析可能通过实现风险分层、辅助化疗监测和早期复发检测来改变结直肠癌的术后管理。

研究设计与样本

  • 前瞻性多中心队列研究,纳入丹麦奥胡斯大学医院、兰讷斯医院和赫宁医院外科2014年5月1日至2017年1月31日的130例Ⅰ至Ⅲ期结直肠癌患者。
  • 采用个体化多重聚合酶链反应二代测序检测术前和术后血浆游离DNA中的ctDNA,共采集829份血浆样本(术前、术后第30天及每3个月一次,随访至3年)。
  • 5例患者停止参与,最终125例纳入分析。

主要发现

  • 患者平均(标准差)年龄67.9(10.1)岁,男性74例(56.9%)。
  • 术前ctDNA在108/122例(88.5%)中可检出;术后纵向ctDNA分析识别了14/16例(87.5%)复发。
  • 术后第30天ctDNA阳性者复发风险为阴性者的7.2倍(HR 7.2,95%CI 2.7-19.0,P<.001);辅助化疗后ctDNA阳性者复发风险为阴性者的17.5倍(HR 17.5,95%CI 5.4-56.5,P<.001),且辅助化疗后ctDNA阳性的7例患者全部复发。
  • 辅助化疗期间和之后监测显示,10例ctDNA阳性患者中3例(30.0%)经辅助化疗清除ctDNA。
  • 根治性治疗后监测期间,ctDNA阳性者复发风险为阴性者的43.5倍(HR 43.5,95%CI 9.8-193.5,P<.001);所有多因素分析中,校正已知临床病理危险因素后ctDNA状态仍与复发独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Novel sensitive methods for detection and monitoring of residual disease can improve postoperative risk stratification with implications for patient selection for adjuvant chemotherapy (ACT), ACT duration, intensity of radiologic surveillance, and, ultimately, outcome for patients with colorectal cancer (CRC). OBJECTIVE: To investigate the association of circulating tumor DNA (ctDNA) with recurrence using longitudinal data from ultradeep sequencing of plasma cell-free DNA in patients with CRC before and after surgery, during and after ACT, and during surveillance. DESIGN, SETTING, AND PARTICIPANTS: In this prospective, multicenter cohort study, ctDNA was quantified in the preoperative and postoperative settings of stages I to III CRC by personalized multiplex, polymerase chain reaction-based, next-generation sequencing. The study enrolled 130 patients at the surgical departments of Aarhus University Hospital, Randers Hospital, and Herning Hospital in Denmark from May 1, 2014, to January 31, 2017. Plasma samples (n = 829) were collected before surgery, postoperatively at day 30, and every third month for up to 3 years. MAIN OUTCOMES AND MEASURES: Outcomes were ctDNA measurement, clinical recurrence, and recurrence-free survival. RESULTS: A total of 130 patients with stages I to III CRC (mean [SD] age, 67.9 [10.1] years; 74 [56.9%] male) were enrolled in the study; 5 patients discontinued participation, leaving 125 patients for analysis. Preoperatively, ctDNA was detectable in 108 of 122 patients (88.5%). After definitive treatment, longitudinal ctDNA analysis identified 14 of 16 relapses (87.5%). At postoperative day 30, ctDNA-positive patients were 7 times more likely to relapse than ctDNA-negative patients (hazard ratio [HR], 7.2; 95% CI, 2.7-19.0; P < .001). Similarly, shortly after ACT ctDNA-positive patients were 17 times (HR, 17.5; 95% CI, 5.4-56.5; P < .001) more likely to relapse. All 7 patients who were ctDNA positive after ACT experienced relapse. Monitoring during and after ACT indicated that 3 of the 10 ctDNA-positive patients (30.0%) were cleared by ACT. During surveillance after definitive therapy, ctDNA-positive patients were more than 40 times more likely to experience disease recurrence than ctDNA-negative patients (HR, 43.5; 95% CI, 9.8-193.5 P < .001). In all multivariate analyses, ctDNA status was independently associated with relapse after adjusting for known clinicopathologic risk factors. Serial ctDNA analyses revealed disease recurrence up to 16.5 months ahead of standard-of-care radiologic imaging (mean, 8.7 months; range, 0.8-16.5 months). Actionable mutations were identified in 81.8% of the ctDNA-positive relapse samples. CONCLUSIONS AND RELEVANCE: Circulating tumor DNA analysis can potentially change the postoperative management of CRC by enabling risk stratification, ACT monitoring, and early relapse detection.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019. PMID: 31070691. doi:10.1001/jamaoncol.2019.0528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。